Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer (Q34535255)

2 August 2017

1 reference

title

Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer (English)

1 reference

2 August 2017

1 reference

J F Robertson

1

1 reference

2 August 2017

1 December 2001

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

2 August 2017

1 reference

2 August 2017

79

1 reference

2 August 2017

1-5

1 reference

2 August 2017

209-212

1 reference

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Tamoxifen in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Gynecologic effects of tamoxifen and the association with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Tamoxifen flare in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900138-8

7 January 2021

10.1016/S0960-0760(01)00138-8

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11850227